How Chamomile Works
Chamomile's main active compound is apigenin (4',5,7-trihydroxyflavone), a flavonoid that acts as a partial agonist at GABA-A receptors — the brain's primary inhibitory receptors. By binding to the benzodiazepine site of these receptors, apigenin enhances GABA's calming signal, reducing neuronal excitability without the dependency risk associated with pharmaceutical benzodiazepines [1][5]. This mechanism explains why chamomile tea before bed has been used across cultures for centuries: it genuinely modulates the neurochemistry of relaxation.
Beyond apigenin, chamomile contains bisabolol and bisabolol oxides (sesquiterpenes with anti-inflammatory activity), chamazulene (formed during steam distillation, with COX-2 inhibiting properties), and multiple flavonoids including luteolin, quercetin, and patuletin that contribute to antioxidant and immune-modulating effects [6].
Anxiety and Mood
Three clinical trials have specifically examined chamomile for generalized anxiety disorder (GAD). The 2009 double-blind RCT by Amsterdam et al. used 1.2% apigenin standardized extract (220 mg/day) and found significantly greater symptom reduction compared to placebo over 8 weeks [1]. The 2016 follow-up by Mao et al. tracked patients for 26 additional weeks and found chamomile significantly delayed symptom relapse when continued long-term, with a hazard ratio for relapse of 2.5 — meaning patients on placebo relapsed two and a half times faster [2].
Sleep Quality
The mechanism overlaps with anxiety reduction: GABA-A receptor activation reduces time to sleep onset and improves sleep continuity. A 2019 meta-analysis of 12 randomized trials found statistically significant improvements in sleep quality scores (standardized mean difference −0.97, 95% CI −1.87 to −0.06), particularly for subjective sleep ratings, daytime functioning, and mood upon waking [3].
Digestive Support
Chamomile has well-documented antispasmodic effects in the gastrointestinal tract. Bisabolol and the flavonoid glycosides reduce smooth muscle spasm, which underlies its traditional use for cramping, gas, and irritable bowel symptoms. Cell and tissue studies show chamomile extract reduces the production of pro-inflammatory cytokines (TNF-α, IL-8) in gut epithelial cells and isolated colon tissue, suggesting a direct anti-inflammatory action on the gut lining [4].
Practical Use
Tea: The most traditional and widely available form. Use 2–3 g of dried flowers steeped in 150 ml of hot water for 5–10 minutes. For sleep, drink 30–45 minutes before bed. For anxiety, 2–3 cups daily provides consistent apigenin exposure.
Standardized extract: For clinical-level effects seen in trials, look for extracts standardized to 1.2% apigenin. Doses used in RCTs were 220–1500 mg daily.
Duration: The anxiety trials suggest chamomile's benefits build over weeks of consistent use rather than occurring immediately.
Safety: Chamomile is well-tolerated. The main caution is allergy — those with ragweed, chrysanthemum, or other Asteraceae family allergies may cross-react. It may potentiate the effects of anticoagulants (coumarin constituents) and sedative medications at high doses. Not recommended during pregnancy due to potential uterine stimulation.
See our valerian page for another GABA-pathway herb with strong sleep evidence, or our lemon balm page for a complementary calming herb often combined with chamomile.
Evidence Review
Randomized Controlled Trials for Anxiety
The earliest high-quality trial, Amsterdam et al. (2009), enrolled 57 adults with DSM-IV-defined mild-to-moderate GAD in a double-blind, placebo-controlled design [1]. Participants received either pharmaceutical-grade chamomile extract standardized to 1.2% apigenin (220 mg/day, titrated to 1100 mg/day) or matching placebo for 8 weeks. The primary outcome was the Hamilton Anxiety Rating Scale (HAM-A). Results showed a significantly greater mean reduction in HAM-A total scores for the chamomile group compared to placebo (−2.15 points difference, P = 0.047). Secondary outcomes including the Hospital Anxiety and Depression Scale and Clinical Global Impression also favored chamomile. The effect size was modest but clinically meaningful for a well-tolerated herbal intervention.
The follow-up trial, Mao et al. (2016), addressed a key question the 2009 study left open: does chamomile prevent relapse when continued long-term? [2] This study enrolled 93 patients with moderate-to-severe GAD who first received 12 weeks of open-label chamomile (1500 mg/day), then randomized treatment responders to either continue chamomile or switch to placebo for 26 additional weeks. The primary finding was time to relapse: 15 of 47 patients on placebo relapsed vs. 9 of 42 on chamomile, and Cox regression showed a hazard ratio of 2.5 (95% CI 1.08–5.77, P = 0.03) for relapse on placebo. Crucially, GAD symptom scores continued to decrease during the continuation phase in the chamomile group but rose in the placebo group, confirming sustained efficacy rather than mere symptom suppression.
Meta-Analyses
Hieu et al. (2019) conducted a systematic review and meta-analysis of 12 randomized and quasi-randomized trials covering state anxiety, GAD, insomnia, and sleep quality [3]. For GAD specifically, pooled analysis of two RCTs (totaling 153 patients) confirmed a significant reduction in HAM-A scores (WMD −5.0, 95% CI −9.03 to −0.98). For sleep quality, a meta-analysis of six studies showed a significant improvement in Pittsburgh Sleep Quality Index (PSQI) scores (SMD −0.97, 95% CI −1.87 to −0.06). The authors rated the overall evidence as moderate quality, noting that trials were methodologically heterogeneous in dosing and patient populations but consistent in direction of effect.
Gut and Anti-Inflammatory Evidence
Sándor et al. (2018) applied a hydroalcoholic chamomile extract to HT-29 human colon adenocarcinoma cells (a standard model for gut epithelial biology) and to isolated rat colon segments stimulated with lipopolysaccharide [4]. Key findings:
- TNF-α production was significantly reduced in LPS-stimulated cells at 100 μg/mL chamomile extract (P < 0.01)
- IL-8, a key recruiter of neutrophils in gut inflammation, was suppressed in a dose-dependent manner
- In isolated colon tissue, the extract reduced the spontaneous contractility of smooth muscle, consistent with antispasmodic activity
- Apigenin-7-glucoside was identified as the primary contributor to the anti-inflammatory activity
These findings map directly to traditional uses for gut cramping and inflammatory bowel symptoms, providing a plausible mechanism for chamomile's digestive benefits.
Phytochemical Basis
The 2022 comprehensive review by Haq et al. consolidates the mechanistic literature on chamomile's active constituents [5]. The key finding is that apigenin's anxiolytic and sedative effects appear to depend specifically on its binding to the benzodiazepine allosteric site of GABA-A receptors, but unlike classical benzodiazepines, apigenin shows partial rather than full agonism, explaining why it produces calming effects without pronounced sedation, respiratory depression, or dependence liability. Bisabolol and chamazulene contribute separate anti-inflammatory effects through COX-2 and LOX pathway inhibition.
Strength of Evidence
- Anxiety (GAD): Moderate. Two dedicated RCTs with consistent positive findings, meta-analysis confirmation. Effect sizes modest but meaningful. Limitations: relatively small sample sizes, both trials by the same research group.
- Sleep quality: Moderate. Meta-analysis of six trials finds consistent improvement in subjective sleep quality. Limitations: most trials used subjective measures rather than polysomnography; trials short (≤4 weeks).
- Digestive support: Preclinical (cell and animal models). Consistent with traditional use and mechanism, but dedicated human RCTs for GI endpoints are lacking.
- Safety: High. Consistent across all trials, with adverse events no different from placebo. Long-term safety established up to 38 weeks in the Mao et al. trial.